| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Oncology, Radiation Oncology Research Unit, Queen’s University, Kingston, ON, Canada.
Correspondence to: Michael D. Brundage, MD, MSc, Radiation Oncology Research Unit, Apps Level 4, Kingston General Hospital, Kingston, ON, Canada K7L 2V7; e-mail: michael.brundage{at}krcc.on.ca
Study objectives: To provide a systematic overview of the literature investigating patient and tumor factors that are predictive of survival for patients with non-small cell lung cancer (NSCLC), and to analyze patterns in the design of these studies in order to highlight problematic aspects of their design and to advocate for appropriate directions of future studies.
Design: A systematic search of the MEDLINE database and a synthesis of the identified literature.
Measurements and results: The database search (January 1990 to July 2001) was carried out combining the MeSH terms prognosis and carcinoma, nonsmall cell lung. Eight hundred eighty-seven articles met the search criteria. These studies identified 169 prognostic factors relating either to the tumor or the host. One hundred seventy-six studies reported multivariate analyses. Concerning 153 studies reporting a multivariate analysis of prognostic factors in patients with early-stage NSCLC, the median number of patients enrolled per study was 120 (range, 31 to 1,281 patients). The median number of factors reported to be significant in univariate analyses was 4 (range, 2 to 14 factors). The median number of factors reported to be significant in multivariate analyses per study was 2 (range, 0 to 6 factors). The median number of studies examining each prognostic factor was 1 (range, 1 to 105 studies). Only 6% of studies addressed clinical outcomes other than patient survival.
Conclusions: While the breadth of prognostic factors studied in the literature is extensive, the scope of factors evaluated in individual studies is inappropriately narrow. Individual studies are typically statistically underpowered and are remarkably heterogeneous with regard to their conclusions. Larger studies with clinically relevant modeling are required to address the usefulness of newly available prognostic factors in defining the management of patients with NSCLC.
Key Words: carcinoma • multivariate analysis • non-small cell lung cancer • prognosis
This article has been cited by other articles:
|
|
 |
|
  A. Potti, S. Mukherjee, R. Petersen, H. K. Dressman, A. Bild, J. Koontz, R. Kratzke, M. A. Watson, M. Kelley, G. S. Ginsburg, et al. A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer N. Engl. J. Med., August 10, 2006; 355(6): 570 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Jones, T. M. Daniel, C. E. Denlinger, B. K. Rundall, M. E. Smolkin, and M. R. Wick Stage IB Nonsmall Cell Lung Cancers: Are They All the Same? Ann. Thorac. Surg., June 1, 2006; 81(6): 1958 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer J. Nucl. Med., April 1, 2006; 47(4): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Williams, H. Sugimura, C. Endo, F. C. Nichols, S. D. Cassivi, M. S. Allen, P. C. Pairolero, C. Deschamps, and P. Yang Predicting Postrecurrence Survival Among Completely Resected Nonsmall-Cell Lung Cancer Patients. Ann. Thorac. Surg., March 1, 2006; 81(3): 1021 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Mulligan, A. D. Meram, C. D. Proctor, H. Wu, K. Zhu, and A. J. Marrogi Unlimited Access to Care: Effect on Racial Disparity and Prognostic Factors in Lung Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark Reporting Recommendations for Tumor Marker Prognostic Studies J. Clin. Oncol., December 20, 2005; 23(36): 9067 - 9072. [Full Text] [PDF]
|
|
|
|
|
|
P. Maione, F. Perrone, C. Gallo, L. Manzione, F. Piantedosi, S. Barbera, S. Cigolari, F. Rosetti, E. Piazza, S. F. Robbiati, et al. Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non--Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study J. Clin. Oncol., October 1, 2005; 23(28): 6865 - 6872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Bronchogenic Carcinoma Cooperative Group of the Sp Survival of 2,991 Patients With Surgical Lung Cancer: The Denominator Effect in Survival Chest, October 1, 2005; 128(4): 2274 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Paull, G. M. Updyke, M. A. Baumann, H. W. Chin, A. G. Little, and S. A. Adebonojo Alcohol Abuse Predicts Progression of Disease and Death in Patients with Lung Cancer Ann. Thorac. Surg., September 1, 2005; 80(3): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, G. M. Clark, and for the Statistics Subcommittee of the NCI-EORTC W Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) J Natl Cancer Inst, August 17, 2005; 97(16): 1180 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takenaka, E. Ogawa, H. Oyanagi, H. Wada, and F. Tanaka Carbonyl Reductase Expression and Its Clinical Significance in Non-Small-Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1972 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nonaka, A. Fabbri, L. Roz, L. Mariani, A. Vecchione, G. W. Moore, L. Tavecchio, C. M. Croce, and G. Sozzi Reduced FEZ1/LZTS1 Expression and Outcome Prediction in Lung Cancer Cancer Res., February 15, 2005; 65(4): 1207 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lopez-Encuentra, J. Astudillo, J. Cerezal, F. Gonzalez-Aragoneses, N. Novoa, A. Sanchez-Palencia, and Bronchogenic Carcinoma Cooperative Group of the Sp Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoang, R. Xu, J. H. Schiller, P. Bonomi, and D. H. Johnson Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data J. Clin. Oncol., January 1, 2005; 23(1): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, E. Chasse, D. Ratschiller, W. Weder, M. Joerger, D. C. Betticher, et al. Circulating Deoxyribonucleic Acid As Prognostic Marker in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy J. Clin. Oncol., October 15, 2004; 22(20): 4157 - 4164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Dubinett, D. Elashoff, and M. Meyerson Assessing Prognosis in Non-Small-Cell Lung Cancer: Avenues to a More Complete Picture? J. Clin. Oncol., August 15, 2004; 22(16): 3209 - 3211. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mazzone, T. Mekhail, and A. C. Arroliga Is Lung Cancer in the Nonsmoker a Different Disease? Chest, August 1, 2004; 126(2): 326 - 329. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, G. Glatting, and S. N. Reske Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker? J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamamoto, Y. Tomita, Y. Hoshida, N. Iizuka, M. Monden, S. Yamamoto, K. Iuchi, and K. Aozasa Expression Level of Valosin-Containing Protein (p97) Is Correlated With Progression and Prognosis of Non-Small-Cell Lung Carcinoma Ann. Surg. Oncol., July 1, 2004; 11(7): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Q. Zhu, F. H. Blackhall, M. Pintilie, P. Iyengar, N. Liu, J. Ho, T. Chomiak, D. Lau, T. Winton, F. A. Shepherd, et al. Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker Clin. Cancer Res., March 15, 2004; 10(6): 1984 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gabor, H. Renner, H. Popper, U. Anegg, O. Sankin, V. Matzi, J. Lindenmann, and F.M. Smolle Juttner Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 439 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Endoh, S. Tomida, Y. Yatabe, H. Konishi, H. Osada, K. Tajima, H. Kuwano, T. Takahashi, and T. Mitsudomi Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction J. Clin. Oncol., March 1, 2004; 22(5): 811 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gessner, C. Woischwill, A. Schumacher, U. Liebers, H. Kuhn, P. Stiehl, K. Jurchott, H.D. Royer, C. Witt, and G. Wolff Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Eur. Respir. J., January 1, 2004; 23(1): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, T. G Gharib, H. Wang, C.-C. Huang, R. Kuick, D. G. Thomas, K. A. Shedden, D. E. Misek, J. M. G. Taylor, T. J. Giordano, et al. Protein profiles associated with survival in lung adenocarcinoma PNAS, November 11, 2003; 100(23): 13537 - 13542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Antoch, J. Stattaus, A. T. Nemat, S. Marnitz, T. Beyer, H. Kuehl, A. Bockisch, J. F. Debatin, and L. S. Freudenberg Non-Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging Radiology, November 1, 2003; 229(2): 526 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, C. Gallo, F. A. Shepherd, A. Illiano, F. Piantedosi, S. F. Robbiati, L. Manzione, S. Barbera, L. Frontini, E. Veltri, et al. Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., August 15, 2003; 21(16): 3025 - 3034. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
